Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation

International Journal of Cancer

Volumn 96, Issue 4, 2001, Pages 221-231

  Epperly, Michael W ^a   Kagan, Valerian E ^b   Sikora, Christine A ^c   Gretton, Joan E ^a   Defilippi, Stacy J ^a   Bar Sagi, Dapha ^a   Greenberger, Joel S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Antioxidant gene therapy; Esophageal damage; Fractionated radiation; MnSOD; Plasmid liposome

Indexed keywords

21 AMINOSTEROID; ALPHA TOCOPHEROL; ANTIOXIDANT; BETA GALACTOSIDASE; GLUTATHIONE PEROXIDASE; HEMAGGLUTININ; LIPOSOME; MANGANESE SUPEROXIDE DISMUTASE; UBIDECARENONE;

ANIMAL TISSUE; ARTICLE; CELL PROTECTION; ESOPHAGITIS; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; GENE THERAPY; INTRAESOPHAGEAL DRUG ADMINISTRATION; LIPID PEROXIDATION; LUNG CANCER; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SURVIVAL; TISSUE INJURY;

ANIMALS; BIOLOGICAL MARKERS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; ESOPHAGITIS; FATTY ACIDS, UNSATURATED; FEMALE; HEMAGGLUTININS; LAC OPERON; LIPID METABOLISM; LIPID PEROXIDATION; LIPOSOMES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; PLASMIDS; RADIOTHERAPY; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 0035921188     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1023     Document Type: Article

References (47)

1. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer
2. Protection against late effects of radiation by S 2-(3-aminopropylamino)-ethylphosphorothioic acid
3. The effect of dose-rate and adriamycin on the tolerance of thoracic radiation in mice
4. Results of Phase II concurrent chemoradiotherapy study using threedimensional conformal radiotherapy with cisplatin and oral etoposide in stage III non-small cell lung carcinoma
5. Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer
6. Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer
7. Radiation and simultaneous cisplatin in non-small cell lung cancer
8. Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of cancer and leukemia Group B (CALGB) 8433 trial
9. Results of a phase III prospective randomized trial comparing standard thoracic radiation therapy to twice daily radiotherapy plus concomitant etoposide/cisplatin chemotherapy in patients with unresectable stage IIIA/B non-small cell lung cancer
10. Randomized trials of radiotherapy alone vs. combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small cell lung cancer: A meta analysis
11. Chemoprotection in anticancer therapy: The emerging role of amifostine (WR-2721)
12. Amifostine, Cisplatin and Vinblastine in metastatid non-small-cell lung cancer: A report of high response rates and prolonged survival
13. Amifostine, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector
14. The pulmonary response to sublethal thoracic irradiation in the rat
15. Low radioprotection by thiol in lung: The role of local tissue oxygenation
16. Protection against irradiation-induced damage to salivary glands by adrenergic agonist administration
17. Modelling the enhancement of fractionated radiotherapy by gene transfer to sensitize tumor cell to radiation
18. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC): Analysis of a Radiation Therapy Oncology Group (RTOG) protocol
19. Estimation of pneumonitis risk in three-dimensional treatment planning using dose/volume histogram analysis
20. Development of multifield three-dimensional conformal radiotherapy of lung cancer using a total lung dose/volume histogram
21. Length of circumferential esophagus within the high dose radiotherapy field predicts for late esophageal dysfunction
22. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small cell lung cancer: Results of Eastern Cooperative Oncology Group 4593
23. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung
24. Transport of aminothiol radioprotectors into mammalian cells: Passive diffusion versus mediated uptake
25. Results of multifield conformal radiation therapy of non-small cell lung carcinoma using multileaf collimation beams
26. Prevention of irradiation-induced esophagitis by intraesophageal plasmid/liposome delivery of the human manganese superoxide dismutase (MnSOD) transgene
27. Decreased pulmonary radiation resistance of manganese superoxide dismutase (MnSOD)-deficient mice is corrected by human manganese superoxide dismutaseplasmid/liposome (SOD2-PL) intratracheal gene therapy
28. Mass spectrometry of prostanoids: F2 isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism
29. Formation of non-cyclooxygenase derived prostanoids (F2 isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro
30. Formation of F2 isoprostanes during aortic endothelial cell-mediated oxidation of low density lipoprotein
31. Random versus selective membrane phospholipid oxidation in apoptosis: Role of phosphatidylserine
32. Sensitive and specific fluorescent probing of oxidative stress in different classes of membrane phospholipids in live cells using metabolically integrated cis-parinaric acid
33. Non-random peroxidation of different classes of membrane phospholipids in live cells detected by metabolically integrated cisparinaric acid
34. Plasmid/liposome transfer of the human manganese superoxide dismutase (MnSOD) transgene prevents ionizing irradiation-induced apoptosis in human esophagus organ explant culture
35. Microassay of phosphorus in total lipid extracts
36. New thiol active fluorophores for intracellular thiols and glutathione measurement
37. Time-dose relationships in the mouse esophagus
38. Radiation pathology and the clinical response of lung and esophagus
39. Radioprotection of tumor and normal tissues by thiophosphate compounds
40. Prevention of late effects of irradiation lung damage by manganese superoxide dismutase gene therapy
41. Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis
42. MnSOD-PL pulmonary radioprotective gene therapy: Modulation of irradiation-induced mRNA for IL-1, TNF-α, and TGF-β correlates with delay of organizing alveolitis/fibrosis
43. Modulation of irradiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy
44. Lipid hydroperoxide-induced apoptosis in human colonic CACo-2 cells is associated with an early loss of cellular redox balance
45. Clustering of apoptotic cells via bystander killing by peroxides
46. Redox state is a central modulator of the balance between selfrenewal and differentiation in a dividing glial precursor cell
47. Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation